title: Statin prescribing for primary prevention of cardiovascular disease: a cross-sectional, observational study.
abstract: BACKGROUND
  The updated (2014) National Institute for Health and Care Excellence (NICE) guideline lowered the recommended threshold for statin prescription from 20% to 10% 10-year cardiovascular disease (CVD) risk.
  
  
  OBJECTIVE
  To determine the characteristics of patients prescribed statins for primary prevention according to their CVD risk.
  
  
  METHODS
  Cross-sectional study in primary care settings in the three east London CCGs (Newham, City and Hackney, and Tower Hamlets).
  
  
  METHODS
  Data were extracted from electronic health records of 930 000 patients registered with 137 of 141 general practices for a year ending 1 April 2014.
  
  
  RESULTS
  Of 341 099 patients aged 30-74 years, excluding those with CVD or diabetes, 22 393 were prescribed statins and had a 10-year CVD risk recorded. Of these, 9828 (43.9%) had a CVD risk ≥20%, 7121 (31.8%) had a CVD risk of 10-19%, and 5444 (24.3%) had a CVD risk <10%. Statins were prescribed to 9828/19 755 (49.7%) of those at ≥20% CVD risk, to 7121/37 111 (19.2%) of those with CVD risk 10-19%, and to 5444/146 676 (3.7%) of those with CVD risk <10%. Statin prescription below the 20% CVD risk threshold targeted individuals in the 10-19% risk band in association with hypertension, high serum cholesterol, positive family history, older age, and south Asian ethnicity.
  
  
  CONCLUSIONS
  This study confirms continuing undertreatment of patients at highest CVD risk (≥20%). GPs prescribed statins to only one-fifth of those in the 10-19% risk band usually in association with known major risk factors. Only 3.7% of individuals below 10% were prescribed statins.
authors.affiliation: Centre for Primary Care and Public Health, Queen Mary University of London, London.
authors.forename: Kate
authors.initials: K
authors.lastname: Homer
authors.affiliation: Centre for Primary Care and Public Health, Queen Mary University of London, London.
authors.forename: Kambiz
authors.initials: K
authors.lastname: Boomla
authors.affiliation: Centre for Primary Care and Public Health, Queen Mary University of London, London.
authors.forename: Sally
authors.initials: S
authors.lastname: Hull
authors.affiliation: Centre for Primary Care and Public Health, Queen Mary University of London, London.
authors.forename: Isabel
authors.initials: I
authors.lastname: Dostal
authors.affiliation: Centre for Primary Care and Public Health, Queen Mary University of London, London.
authors.forename: Rohini
authors.initials: R
authors.lastname: Mathur
authors.affiliation: Centre for Primary Care and Public Health, Queen Mary University of London, London.
authors.forename: John
authors.initials: J
authors.lastname: Robson
mesh_terms: D000368:Aged; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D003430:Cross-Sectional Studies; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000453:epidemiology; D004739:England / Q000453:epidemiology; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D008131:London / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011320:Primary Health Care; D011322:Primary Prevention / Q000379:methods*; D018570:Risk Assessment
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: cardiovascular prevention; cardiovascular risk; primary care; statins